JACC: Cardiooncology

Papers
(The H4-Index of JACC: Cardiooncology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Editorial Board127
Full Issue PDF120
Full Issue PDF110
Atrial Fibrillation in Patients With Cancer110
Full Issue PDF100
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy91
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque88
Epigenomics of Cardio-Oncology87
Priorities in Cardio-Oncology87
Hormonal Therapy and Cardiovascular Health81
Cardiovascular Safety in Oncology Clinical Trials63
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies63
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part56
Cardiac Magnetic Resonance in Cardio-Oncology56
Balancing Promise and Evidence51
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients51
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy48
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes48
Full Issue PDF47
Full Issue PDF47
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy45
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD45
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors44
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients43
Cardiac Risk Stratification Before Lung Cancer Radiation42
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy41
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis41
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma40
Frailty38
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA38
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis36
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer33
Permissive Cardiotoxicity33
Cancer Immunotherapy Beyond Checkpoint Blockade33
0.09632396697998